Elizabeth C Oelsner1,2, Laura R Loehr3, Ashley G Henderson4, Kathleen M Donohue1, Paul L Enright5, Ravi Kalhan6, Christian M Lo Cascio1, Andrew Ries7, Neomi Shah8, Benjamin M Smith1,9, Wayne D Rosamond3, R Graham Barr1,2. 1. 1 Department of Medicine and. 2. 2 Department of Epidemiology, Columbia University, New York, New York. 3. 3 Department of Epidemiology and. 4. 4 Department of Medicine, University of North Carolina, Chapel Hill, North Carolina. 5. 5 Department of Medicine, University of Arizona, Tucson, Arizona. 6. 6 Department of Medicine, Northwestern University, Evanston, Illinois. 7. 7 Department of Medicine, University of California, San Diego, La Jolla, California. 8. 8 Icahn School of Medicine at Mount Sinai Hospital, New York, New York; and. 9. 9 Department of Medicine, McGill University, Montreal, Quebec, Canada.
Abstract
RATIONALE: One in 12 adults has chronic obstructive pulmonary disease or asthma. Acute exacerbations of these chronic lower respiratory diseases (CLRDs) are a major cause of morbidity and mortality. Valid approaches to classifying cases and exacerbations in the general population are needed to facilitate prevention research. OBJECTIVES: To assess the feasibility, reproducibility, and performance of a protocol to identify CLRD cases and exacerbations triggering emergency department (ED) visits or hospitalizations in cohorts of patients derived from general populations of adults. METHODS: A protocol was developed to classify CLRD cases and severe exacerbations on the basis of review of medical records. ED and inpatient medical records were ascertained prospectively in the Hispanic Community Health Study/Study of Latinos, and inpatient records were retrospectively identified by administrative codes in the Multi-Ethnic Study of Atherosclerosis. "Probable" exacerbations were defined as a physician's diagnosis of CLRD with acute respiratory symptoms. "Highly probable" exacerbations additionally required systemic corticosteroid therapy, and "definite" exacerbations required airflow limitation or evidence of CLRD on imaging studies. Adjudicated results were compared with CLRD cases identified by spirometry and self-report, and with an administrative definition of exacerbations. MEASUREMENTS AND MAIN RESULTS: Protocol-based classification was completed independently by two physicians for 216 medical records (56 ED visits and 61 hospitalizations in the Hispanic Community Health Study/Study of Latinos; 99 hospitalizations in the Multi-Ethnic Study of Atherosclerosis). Reviewer disagreement occurred in 2-5% of cases and 4-8% of exacerbations. Eighty-nine percent of records were confirmed as at least probable CLRD cases. Fifty-six percent of confirmed CLRD cases had airflow limitation on the basis of baseline study spirometry. Of records that described CLRD as the primary discharge diagnosis code, an acute exacerbation was confirmed as at least probable for 96% and as highly probable or definite for 77%. Only 50% of records with CLRD as a secondary code were confirmed, although such records accounted for over half of all confirmed exacerbations. CONCLUSIONS: CLRD cases and severe exacerbations without preceding documentation of airflow limitation are identified frequently in population-based cohorts of persons. A primary discharge diagnosis of CLRD is specific but insensitive for defining exacerbations. Protocol-based classification of medical records may be appropriate to supplement and to validate identification of CLRD cases and exacerbations in general population studies. Clinical trials registered with www.clinicaltrials.gov (NCT00005487 and NCT02060344).
RATIONALE: One in 12 adults has chronic obstructive pulmonary disease or asthma. Acute exacerbations of these chronic lower respiratory diseases (CLRDs) are a major cause of morbidity and mortality. Valid approaches to classifying cases and exacerbations in the general population are needed to facilitate prevention research. OBJECTIVES: To assess the feasibility, reproducibility, and performance of a protocol to identify CLRD cases and exacerbations triggering emergency department (ED) visits or hospitalizations in cohorts of patients derived from general populations of adults. METHODS: A protocol was developed to classify CLRD cases and severe exacerbations on the basis of review of medical records. ED and inpatient medical records were ascertained prospectively in the Hispanic Community Health Study/Study of Latinos, and inpatient records were retrospectively identified by administrative codes in the Multi-Ethnic Study of Atherosclerosis. "Probable" exacerbations were defined as a physician's diagnosis of CLRD with acute respiratory symptoms. "Highly probable" exacerbations additionally required systemic corticosteroid therapy, and "definite" exacerbations required airflow limitation or evidence of CLRD on imaging studies. Adjudicated results were compared with CLRD cases identified by spirometry and self-report, and with an administrative definition of exacerbations. MEASUREMENTS AND MAIN RESULTS: Protocol-based classification was completed independently by two physicians for 216 medical records (56 ED visits and 61 hospitalizations in the Hispanic Community Health Study/Study of Latinos; 99 hospitalizations in the Multi-Ethnic Study of Atherosclerosis). Reviewer disagreement occurred in 2-5% of cases and 4-8% of exacerbations. Eighty-nine percent of records were confirmed as at least probable CLRD cases. Fifty-six percent of confirmed CLRD cases had airflow limitation on the basis of baseline study spirometry. Of records that described CLRD as the primary discharge diagnosis code, an acute exacerbation was confirmed as at least probable for 96% and as highly probable or definite for 77%. Only 50% of records with CLRD as a secondary code were confirmed, although such records accounted for over half of all confirmed exacerbations. CONCLUSIONS: CLRD cases and severe exacerbations without preceding documentation of airflow limitation are identified frequently in population-based cohorts of persons. A primary discharge diagnosis of CLRD is specific but insensitive for defining exacerbations. Protocol-based classification of medical records may be appropriate to supplement and to validate identification of CLRD cases and exacerbations in general population studies. Clinical trials registered with www.clinicaltrials.gov (NCT00005487 and NCT02060344).
Authors: Amany F Elbehairy; Natya Raghavan; Sicheng Cheng; Ling Yang; Katherine A Webb; J Alberto Neder; Jordan A Guenette; Mahmoud I Mahmoud; Denis E O'Donnell Journal: Chest Date: 2015-05 Impact factor: 9.410
Authors: Elizabeth A Regan; David A Lynch; Douglas Curran-Everett; Jeffrey L Curtis; John H M Austin; Philippe A Grenier; Hans-Ulrich Kauczor; William C Bailey; Dawn L DeMeo; Richard H Casaburi; Paul Friedman; Edwin J R Van Beek; John E Hokanson; Russell P Bowler; Terri H Beaty; George R Washko; MeiLan K Han; Victor Kim; Song Soo Kim; Kunihiro Yagihashi; Lacey Washington; Charlene E McEvoy; Clint Tanner; David M Mannino; Barry J Make; Edwin K Silverman; James D Crapo Journal: JAMA Intern Med Date: 2015-09 Impact factor: 21.873
Authors: Paul D Sorlie; Larissa M Avilés-Santa; Sylvia Wassertheil-Smoller; Robert C Kaplan; Martha L Daviglus; Aida L Giachello; Neil Schneiderman; Leopoldo Raij; Gregory Talavera; Matthew Allison; Lisa Lavange; Lloyd E Chambless; Gerardo Heiss Journal: Ann Epidemiol Date: 2010-08 Impact factor: 3.797
Authors: Carlos H Martinez; Victor Kim; Yahong Chen; Ella A Kazerooni; Susan Murray; Gerard J Criner; Jeffrey L Curtis; Elizabeth A Regan; Emily Wan; Craig P Hersh; Edwin K Silverman; James D Crapo; Fernando J Martinez; Meilan K Han Journal: Respir Med Date: 2013-11-15 Impact factor: 3.415
Authors: Surya P Bhatt; Pallavi P Balte; Joseph E Schwartz; Patricia A Cassano; David Couper; David R Jacobs; Ravi Kalhan; George T O'Connor; Sachin Yende; Jason L Sanders; Jason G Umans; Mark T Dransfield; Paulo H Chaves; Wendy B White; Elizabeth C Oelsner Journal: JAMA Date: 2019-06-25 Impact factor: 56.272
Authors: Elizabeth C Oelsner; Pallavi P Balte; Patricia A Cassano; David Couper; Paul L Enright; Aaron R Folsom; John Hankinson; David R Jacobs; Ravi Kalhan; Robert Kaplan; Richard Kronmal; Leslie Lange; Laura R Loehr; Stephanie J London; Ana Navas Acien; Anne B Newman; George T O'Connor; Joseph E Schwartz; Lewis J Smith; Fawn Yeh; Yiyi Zhang; Andrew E Moran; Stanford Mwasongwe; Wendy B White; Sachin Yende; R Graham Barr Journal: Am J Epidemiol Date: 2018-11-01 Impact factor: 4.897
Authors: Emily S Wan; Pallavi Balte; Joseph E Schwartz; Surya P Bhatt; Patricia A Cassano; David Couper; Martha L Daviglus; Mark T Dransfield; Sina A Gharib; David R Jacobs; Ravi Kalhan; Stephanie J London; Ana Navas-Acien; George T O'Connor; Jason L Sanders; Benjamin M Smith; Wendy White; Sachin Yende; Elizabeth C Oelsner Journal: JAMA Date: 2021-12-14 Impact factor: 157.335
Authors: Pallavi P Balte; Paulo H M Chaves; David J Couper; Paul Enright; David R Jacobs; Ravi Kalhan; Richard A Kronmal; Laura R Loehr; Stephanie J London; Anne B Newman; George T O'Connor; Joseph E Schwartz; Benjamin M Smith; Lewis J Smith; Wendy B White; Sachin Yende; Elizabeth C Oelsner Journal: JAMA Intern Med Date: 2020-05-01 Impact factor: 21.873
Authors: Elizabeth C Oelsner; Pallavi P Balte; Morgan E Grams; Patricia A Cassano; David R Jacobs; R Graham Barr; Kristin M Burkart; Ravi Kalhan; Richard Kronmal; Laura R Loehr; George T O'Connor; Joseph E Schwartz; Michael Shlipak; Russell P Tracy; Michael Y Tsai; Wendy White; Sachin Yende Journal: Am J Respir Crit Care Med Date: 2019-02-01 Impact factor: 30.528
Authors: Elizabeth C Oelsner; Benjamin M Smith; Eric A Hoffman; Ravi Kalhan; Kathleen M Donohue; Joel D Kaufman; Jennifer N Nguyen; Ani W Manichaikul; Jerome I Rotter; Erin D Michos; David R Jacobs; Gregory L Burke; Aaron R Folsom; Joseph E Schwartz; Karol Watson; R Graham Barr Journal: Ann Am Thorac Soc Date: 2018-06
Authors: John P Donnelly; Yuling Dai; Lisandro D Colantonio; Hong Zhao; Monika M Safford; John W Baddley; Paul Muntner; Henry E Wang Journal: BMC Med Res Methodol Date: 2020-03-04 Impact factor: 4.615